Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

PharmaMar SA today announced that a registration trial in relapsed/refractory multiple myeloma patients has been initiated with Aplidin(R) (plitidepsin) in combination with dexamethasone versus dexamethasone alone.

9 Jun 2010

CPRIT presents a $300,000 check to UNT Health Science Center for cancer research

The Cancer Prevention and Research Institute of Texas recently presented a $300,000 check to the University of North Texas Health Science Center. The check was accepted by the UNT Health Science Center Provost Thomas Yorio, Ph.D., and Richard Kurz, Ph.D., dean of the School of Public Health.

9 Jun 2010

American Diversified Holdings enters Mobile Health Care Market

American Diversified Holdings Corporation has today announced its intention to enter the Mobile Health Care Market as the medical profession gears up to go electronic not only for medical records but also for direct patient monitoring and information.

9 Jun 2010

Springhill retirement community opens Woodlands Memory Support Neighborhood

Families with loved ones who have memory challenges will breathe a sigh of relief on June 11, when Springhill retirement community opens the doors to the Woodlands Memory Support Neighborhood. A presentation by Springhill Executive Director Jim Schneider and Ed Thomas, CEO of Asbury Communities, the management company for Springhill, will begin at 11:00 a.m. with tours of the new neighborhood to follow.

8 Jun 2010

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Adeona Pharmaceuticals, Inc. announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).

7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

The liver scarring of α1-antitrypsin deficiency, the most common genetic cause for which children undergo liver transplantation, might be reversed or prevented with a medication that has long been used to treat seizures, according to findings from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine that will published in Science and are available online today through the Science Express website.

4 Jun 2010

New UNC-Olympus Research Imaging Center opens doors

The University of North Carolina (UNC) at Chapel Hill today opened the doors of a new facility designed to be one of the world's most sophisticated research centers devoted to life science imaging. The new UNC-Olympus Research Imaging Center provides researchers with advanced microscopes and camera equipment, software, consultation and expertise, in an environment intended to encourage the highest levels of scientific inquiry.

From Evident Corporation - Life Sciences 4 Jun 2010

Special dementia care plan does not slow functional decline compared with usual care: Study

A special dementia care plan, involving regular assessments of patients with Alzheimer's disease in specialist memory clinics, does not slow functional decline compared with usual care, finds a study published on bmj.com today.

4 Jun 2010

WisTa Laboratories announces collaborative R&D agreement with Bayer Schering Pharma

WisTa Laboratories Ltd, a wholly owned subsidiary of TauRx Pharmaceuticals, announced today that they have entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer's disease (AD) and related disorders are currently being diagnosed and treated.

4 Jun 2010

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.

4 Jun 2010

Nutrient found in maternal diet provide lasting cognitive, emotional benefits to people with Down syndrome: Study

A nutrient found in egg yolks, liver and cauliflower taken by mothers during pregnancy and nursing may offer lifelong "dramatic" health benefits to people with Down syndrome.

4 Jun 2010

Amorfix Life Sciences signs licensing agreement with PREVENT

Amorfix Life Sciences Ltd. and Pan-Provincial Vaccine Enterprise Inc. of Saskatoon, Saskatchewan, today announced that the two groups have entered into a licensing agreement granting PREVENT exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis vaccines.

3 Jun 2010

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Cure Alzheimer's Fund recently awarded the University of Texas Health Science Center at Houston and the University of Houston a $150,000 grant to fund innovative research on Alzheimer's disease, which currently affects 5.3 million Americans and their families and is the most common cause of dementia in the elderly.

3 Jun 2010

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Q Therapeutics, Inc. announced today that Piotr Walczak, M.D., of Johns Hopkins University has received notification of a $1,000,000 grant to be awarded by the Maryland Stem Cell Research Fund (MSCRF) which will enable further study of Q's human neural glial cell product Q-Cells® in preclinical models of demyelinating disease.

2 Jun 2010

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease.

2 Jun 2010

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept. Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans.

2 Jun 2010

Survey: 58% of Australians worry about brain health, age-related degenerative brain disease

The majority of Australians (58%) are worried about their brain health and the threat of age-related degenerative brain disease, according to a new survey. The national survey was commissioned by leading medical research institute Neuroscience Research Australia and polled 1000 Australians aged 18 to over 75.

2 Jun 2010

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

1 Jun 2010

Amorfix provides update on development of blood test for vCJD

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, provides an update on the development of a blood test for vCJD, one of its six product development programs.

31 May 2010

Alzheimer's Disease News and Research

Further Reading

PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

CPRIT presents a $300,000 check to UNT Health Science Center for cancer research

American Diversified Holdings enters Mobile Health Care Market

Springhill retirement community opens Woodlands Memory Support Neighborhood

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

New UNC-Olympus Research Imaging Center opens doors

Special dementia care plan does not slow functional decline compared with usual care: Study

WisTa Laboratories announces collaborative R&D agreement with Bayer Schering Pharma

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Nutrient found in maternal diet provide lasting cognitive, emotional benefits to people with Down syndrome: Study

Amorfix Life Sciences signs licensing agreement with PREVENT

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

Survey: 58% of Australians worry about brain health, age-related degenerative brain disease

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

Amorfix provides update on development of blood test for vCJD

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News